论文部分内容阅读
人重组白细胞介素2(rhIL-2)是T淋巴细胞产生的一种细胞因子,在抗肿瘤、抗感染等方面具有应用价值.但rhIL-2在体内半衰期短,稳定性差,限制了其临床应用.改变细胞因子类药物的剂型,可延长细胞因子类药物在体内的半衰期,增强其稳定性.国外已有报道,将白细胞介素-2包于脂质体中可明显增加它的稳定性和体内的生物利用度,从而提高IL-2的疗效.本文以对IL-2敏感的B16黑色素瘤为靶细胞,研究了IL-2脂质体的抗肿瘤作用,以期为白细胞介素-2脂质体药物的应用提供实验依据.
Human recombinant interleukin-2 (rhIL-2) is a cytokine produced by T lymphocytes and has application value in anti-tumor, anti-infection, etc. However, rhIL-2 has short half-life in vivo and poor stability, limiting its clinical Application. Changing the dosage form of cytokines can prolong the half-life of cytokines in the body and enhance their stability. It has been reported abroad that the inclusion of interleukin-2 in liposomes can significantly increase its stability. And in vivo bioavailability, thereby enhancing the efficacy of IL-2. In this paper, IL-2 sensitive B16 melanoma as a target cell, to study the anti-tumor effect of IL-2 liposome, with a view to interleukin-2 The use of liposomal drugs provides experimental evidence.